Subsequent pregnancy outcome in women with a history of preeclampsia and/or HELLP syndrome;Incidence et facteurs de risque d'une complication vasculaire lors de la grossesse suivant un antécédent de prééclampsie et/ou de HELLP syndrome

Gynecologie Obstetrique et Fertilite

Volumn 38, Issue 3, 2010, Pages 166-172

  Cathelain Soland, S ^a   Coulon, C ^a   Subtil, D ^a,b   Houfflin Debarge, V ^a,b   Deruelle, P ^a,b  

^a LILLE UNIVERSITY HOSPITAL   (France)

^b UNIV LILLE   (France)

Author keywords

Abruptio placentae; Pregnancy; Pregnancy induced hypertension; Recurrence; Risk factors; Small for gestational age

Indexed keywords

ADULT; ARTICLE; CONTROLLED STUDY; DELIVERY; FEMALE; FOLLOW UP; GESTATION PERIOD; HELLP SYNDROME; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; MATERNAL HYPERTENSION; MEDICAL RECORD REVIEW; NEWBORN; OBESITY; PREECLAMPSIA; PREGNANCY COMPLICATION; PREGNANCY OUTCOME; RISK FACTOR; SMALL FOR DATE INFANT; SOLUTIO PLACENTAE; VASCULAR DISEASE;

EID: 77950029991     PISSN: 12979589     EISSN: 17696682     Source Type: Journal    
DOI: 10.1016/j.gyobfe.2009.12.015     Document Type: Article

References (35)

1. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005;365(9461):785-99.
2. ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 2002;77(1):67-75.
3. Boukerrou M, Bresson S, Collinet P, Delelis A, Deruelle P, Houfflin-Debarge V, et al. Factors associated with uterine artery Doppler anomalies in patients with preeclampsia. Hypertens Pregnancy 2009;28(2):178-89.
4. Deruelle P, Coudoux E, Ego A, Houfflin-Debarge V, Codaccioni X, Subtil D. Risk factors for post-partum complications occurring after preeclampsia and HELLP syndrome. A study in 453 consecutive pregnancies. Eur J Obstet Gynecol Reprod Biol 2006;125(1):59-65.
5. Roberts JM, Cooper DW. Pathogenesis and genetics of pre-eclampsia. Lancet 2001;357(9249):53-6.
6. Tsatsaris V, Fournier T, Winer N. Pathophysiologie de la prééclampsie. J Gynecol Obstet Biol Reprod (Paris) 2008;37(1):16-23.
7. Chames MC, Haddad B, Barton JR, Livingston JC, Sibai BM. Subsequent pregnancy outcome in women with a history of HELLP syndrome at ≤ 28 weeks of gestation. Am J Obstet Gynecol 2003;188(6):1504-7 [discussion 7-8].
8. Dukler D, Porath A, Bashiri A, Erez O, Mazor M. Remote prognosis of primiparous women with preeclampsia. Eur J Obstet Gynecol Reprod Biol 2001;96(1):69-74.
9. Hjartardottir S, Leifsson BG, Geirsson RT, Steinthorsdottir V. Recurrence of hypertensive disorder in second pregnancy. Am J Obstet Gynecol 2006;194(4):916-20.
10. Lie RT, Rasmussen S, Brunborg H, Gjessing HK, Lie-Nielsen E, Irgens LM. Fetal and maternal contributions to risk of preeclampsia: population-based study. BMJ 1998;316(7141):1343-7.
11. Makkonen N, Heinonen S, Kirkinen P. Obstetric prognosis in second pregnancy after preeclampsia in first pregnancy. Hypertens Pregnancy 2000;19(2):173-81.
12. Mostello D, Catlin TK, Roman L, Holcomb Jr WL, Leet T. Preeclampsia in the parous woman: who is at risk? Am J Obstet Gynecol 2002;187(2):425-9.
13. Rasmussen S, Irgens LM, Albrechtsen S, Dalaker K. Predicting preeclampsia in the second pregnancy from low birth weight in the first pregnancy. Obstet Gynecol 2000;96(5 Pt 1):696-700.
14. Sibai BM, El-Nazer A, Gonzalez-Ruiz A. Severe preeclampsia-eclampsia in young primigravid women: subsequent pregnancy outcome and remote prognosis. Am J Obstet Gynecol 1986;155(5):1011-6.
15. Sibai BM, Mercer B, Sarinoglu C. Severe preeclampsia in the second trimester: recurrence risk and long-term prognosis. Am J Obstet Gynecol 1991;165(5 Pt 1):1408-12.
16. Sullivan CA, Magann EF, Perry Jr KG, Roberts WE, Blake PG, Martin Jr JN. The recurrence risk of the syndrome of hemolysis, elevated liver enzymes, and low platelets (HELLP) in subsequent gestations. Am J Obstet Gynecol 1994;171(4):940-3.
17. van Pampus MG, Wolf H, Mayruhu G, Treffers PE, Bleker OP. Long-term follow-up in patients with a history of (H)ELLP syndrome. Hypertens Pregnancy 2001;20(1):15-23.
18. van Rijn BB, Hoeks LB, Bots ML, Franx A, Bruinse HW. Outcomes of subsequent pregnancy after first pregnancy with early-onset preeclampsia. Am J Obstet Gynecol 2006;195(3):723-8.
19. Barton JR, Sibai BM. Prediction and prevention of recurrent preeclampsia. Obstet Gynecol 2008;112(2 Pt 1):359-72.
20. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA 1991;266(2):237-41.
21. North RA, Taylor R, Li Zhou R, Schellenberg JC. The relationship of smoking, preeclampsia, and secretory component. Am J Obstet Gynecol 2000;183(1):136-9.
22. Skomsvoll JF, Baste V, Irgens LM, Ostensen M. The recurrence risk of adverse outcome in the second pregnancy in women with rheumatic disease 1. Obstet Gynecol 2002;100(6):1196-202.
23. Brown MA, Mackenzie C, Dunsmuir W, Roberts L, Ikin K, Matthews J, et al. Can we predict recurrence of pre-eclampsia or gestational hypertension? BJOG 2007;114(8):984-93.
24. Campbell DM, MacGillivray I, Carr-Hill R. Preeclampsia in second pregnancy. Br J Obstet Gynaecol 1985;92(2):131-40.
25. Hnat MD, Sibai BM, Caritis S, Hauth J, Lindheimer MD, MacPherson C, et al. Perinatal outcome in women with recurrent preeclampsia compared with women who develop preeclampsia as nulliparas. Am J Obstet Gynecol 2002;186(3):422-6.
26. Poston L, Briley AL, Seed PT, Kelly FJ, Shennan AH. Vitamin C and vitamin E in pregnant women at risk for preeclampsia (VIP trial): randomised placebo-controlled trial. Lancet 2006;367(9517):1145-54.
27. Skjaerven R, Wilcox AJ, Lie RT. The interval between pregnancies and the risk of preeclampsia. N Engl J Med 2002;346(1):33-8.
28. Spinnato 2nd JA, Freire S, Pinto ESJL, Cunha Rudge MV, Martins-Costa S, Koch MA, et al. Antioxidant therapy to prevent preeclampsia: a randomized controlled trial. Obstet Gynecol 2007;110(6):1311-8.
29. Trogstad L, Skrondal A, Stoltenberg C, Magnus P, Nesheim BI, Eskild A. Recurrence risk of preeclampsia in twin and singleton pregnancies. Am J Med Genet A 2004;126A(1):41-5.
30. Martinez Abundis E, Gonzalez Ortiz M, Quinones Galvan A, Ferrannini E. Hyperinsulinemia in glucose-tolerant womenwith preeclampsia. A controlled study. Am J Hypertens 1996;9(6):610-4.
31. Bretelle F, Sabatier F, Shojai R, Agostini A, Dignat-George F, Blanc B, et al. New insight in physiopathology of preeclampsia and intra-uterine growth retardation: role of inflammation. Gynecol Obstet Fertil 2004;32(6):482-9.
32. Ness RB, Sibai BM. Shared and disparate components of the pathophysiologies of fetal growth restriction and preeclampsia. Am J Obstet Gynecol 2006;195(1):40-9.
33. Laivuori H, Gallaher MJ, Collura L, Crombleholme WR, Markovic N, Rajakumar A, et al. Relationships between maternal plasma leptin, placental leptin mRNA and protein in normal pregnancy, preeclampsia and intrauterine growth restriction without preeclampsia. Mol Hum Reprod 2006;12(9):551-6.
34. Ogawa M, Yanoma S, Nagashima Y, Okamoto N, Ishikawa H, Haruki A, et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta 2007;28(2-3):224-32.
35. Askie LM, Duley L, Henderson-Smart DJ, Stewart LA. Antiplatelet agents for prevention of preeclampsia: ameta-analysis of individual patient data. Lancet 2007;369(9575):1791-8.